High serum levels of soluble PD-L1 were found to correlate with tumor aggressiveness (tumor size and stage) and poor prognosis of HCC, while serum levels of soluble PD-L1 were significantly increased in HCC patients treated with SBRT (P<0.001). The gene discussed is CD274; the disease is hepatocellular carcinoma.